Features | Partner Sites | Information | LinkXpress
Sign In
SIEMENS DIAGNOSTICS

Cotinine Assay Rapidly Confirms Nonsmoking Status

By Labmedica International staff writers
Posted on 13 Jan 2014
Image: The Saliva SmokeScreen test includes a saliva collecting device which consists of a white collecting swab and vial (Photo courtesy of GFC Diagnostics).
Image: The Saliva SmokeScreen test includes a saliva collecting device which consists of a white collecting swab and vial (Photo courtesy of GFC Diagnostics).
Image: Development of a pink color indicates a positive Saliva Smokescreen result (Photo courtesy of GFC Diagnostics).
Image: Development of a pink color indicates a positive Saliva Smokescreen result (Photo courtesy of GFC Diagnostics).
A novel, rapid and user-friendly diagnostic test provides confirmation that an individual has stopped smoking tobacco cigarettes.

In addition to being healthier, not smoking can significantly reduce the cost of health insurance. However, until recently it has not been easy to prove diagnostically that an individual was a non-smoker.

Toward this end, the British biotech company GFC Diagnostics (Bicester, United Kingdom) has introduced the Saliva SmokeScreen test. The test detects cotinine, a breakdown product of nicotine. Cotinine has an in vivo half-life of approximately 20 hours, and is typically detectable for several days (up to one week) after the use of tobacco. The level of cotinine in the blood is proportionate to the amount of exposure to tobacco smoke, so it is a valuable indicator of tobacco smoke exposure. The newly improved Saliva SmokeScreen assay is more sensitive and specific than its previous version, being reported at 90% and 98% respectively, with an accuracy of 94%.

To test for nicotine exposure the user places the test swab in the mouth to absorb 1.5 mL of saliva. The swab is removed from the mouth, placed inside the plastic collector, and pushed against the grid half way down. This procedure squeezes the saliva into the bottom of the collector. The presence of cotinine causes a color change that is visible after one minute. The optimal time to read the result is six minutes. If read before five minutes, the result will be positive, but less than the correct result. After six minutes, it will be more than the true result.

The Saliva SmokeScreen test has been certified as a tool in a British health insurer's program to verify nonsmoking in their policy holders, so they can qualify for its unique nonsmoker cash back reward. Dr. Graham Cope, technical director at GFC Diagnostics and an honorary senior research fellow at the University of Birmingham (United Kingdom), said, "Smoking is an important risk factor for many chronic diseases, such as respiratory diseases, cardiovascular disease, and diabetes. It also causes blood pressure to rise and is linked with high cholesterol levels. We are pleased the SmokeScreen test has been chosen as the means to monitor smoking in this program."

Related Links:

GFC Diagnostics
University of Birmingham



comments powered by Disqus

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.